Published in Drug Law Weekly, March 24th, 2009
"We address here whether therapeutic use of FTY720 in simian human immunodeficiency virus (SHIV)-infected rhesus macaques could also decrease viraemia. FTY720 was administered intravenously to three SHIV(SF162P3)-infected macaques at 39, 7 or 6 weeks of infection; three control macaques (47, 48 or 6 weeks of infection) did...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-03-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.